Company Filing History:
Years Active: 2019-2022
Title: The Innovative Contributions of Felipe José Oliveira Varum
Introduction
Felipe José Oliveira Varum is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of delayed release drug formulations. With a total of 2 patents, his work has the potential to enhance drug delivery systems and improve patient outcomes.
Latest Patents
Varum's latest patents focus on a delayed release formulation that includes a core containing a drug and a specialized delayed release coating. This innovative formulation accelerates the release of the drug in the colon by incorporating an isolation layer between the core and the coating. The delayed release coating consists of an inner layer and an outer layer. The outer layer is made from a pH dependently soluble polymeric material with a pH threshold of about 5 or above. The inner layer is composed of a soluble polymeric material that is effective in intestinal or gastrointestinal fluid. This material can be a polycarboxylic acid polymer that is at least partially neutralized or a non-ionic polymer, which may include additives such as a buffer agent and a base.
Career Highlights
Felipe José Oliveira Varum is currently employed at Tillotts Pharma AG, where he continues to innovate in the pharmaceutical industry. His expertise in drug formulation has positioned him as a valuable asset to the company and the field at large.
Collaborations
Throughout his career, Varum has collaborated with several professionals, including Roberto Carlos Bravo González and Thomas Buser. These collaborations have likely contributed to the advancement of his research and the successful development of his patents.
Conclusion
Felipe José Oliveira Varum's contributions to delayed release drug formulations exemplify the importance of innovation in the pharmaceutical industry. His work not only enhances drug delivery systems but also holds promise for improving therapeutic outcomes for patients.